Chang H K, Gendelman R, Lisziewicz J, Gallo R C, Ensoli B
Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Gene Ther. 1994 May;1(3):208-16.
The tat gene product (Tat) of HIV-1 is an early regulatory protein necessary for viral gene expression and replication. Tat may also play a role as an extracellular protein in both HIV-1 replication and AIDS-associated disorders such as Kaposi's sarcoma. Thus, Tat represents a good target for gene therapy against AIDS. Here we show that when vectors expressing antisense tat RNA are transiently transfected into CD4+ cells, they block about 70% of HIV-1 replication and inhibit the rescue of Tat-defective HIV-1 proviruses by inhibition of Tat protein expression and consequent lack of transcriptional activation of the HIV-promoter. However, antisense tat vectors cannot block the activity of extracellular Tat protein. Another tat inhibitory construct (poly-Tat-activation response; TAR) previously suggested to inhibit HIV-1 transactivation by sequestering the Tat protein, inhibited the activity of extracellular Tat, but like antisense tat RNA did not completely block viral gene expression and replication. These results suggested that one mode of inhibition is not sufficient to block Tat function. However, when the antisense tat and the poly-TAR constructs were combined HIV-1 gene expression was completely blocked (94-98%), suggesting that a combination of inhibitory genes blocking Tat by sequential steps may be a better approach for AIDS gene therapy.
HIV-1的tat基因产物(Tat)是一种早期调节蛋白,对病毒基因表达和复制至关重要。Tat作为一种细胞外蛋白,可能在HIV-1复制以及诸如卡波西肉瘤等艾滋病相关疾病中发挥作用。因此,Tat是抗艾滋病基因治疗的一个良好靶点。在此我们表明,当将表达反义tat RNA的载体瞬时转染到CD4+细胞中时,它们能阻断约70%的HIV-1复制,并通过抑制Tat蛋白表达以及随之而来的HIV启动子转录激活缺失来抑制Tat缺陷型HIV-1前病毒的拯救。然而,反义tat载体无法阻断细胞外Tat蛋白的活性。先前提出的另一种tat抑制构建体(多Tat-激活反应元件;TAR)通过隔离Tat蛋白来抑制HIV-1反式激活,它抑制了细胞外Tat的活性,但与反义tat RNA一样,并未完全阻断病毒基因表达和复制。这些结果表明,单一的抑制模式不足以阻断Tat功能。然而,当将反义tat和多TAR构建体联合使用时,HIV-1基因表达被完全阻断(94%-98%),这表明通过连续步骤阻断Tat的抑制基因组合可能是艾滋病基因治疗的一种更好方法。